These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 11758582

  • 1. Patenting drug products: anticipating Hatch-Waxman issues during the claims drafting process.
    Mahn TG.
    Food Drug Law J; 1999; 54(2):245-53. PubMed ID: 11758582
    [No Abstract] [Full Text] [Related]

  • 2. The Hatch-Waxman Act during patent prosecution and beyond.
    Mahn TG.
    Food Drug Law J; 1999; 54(2):233-6. PubMed ID: 11758578
    [No Abstract] [Full Text] [Related]

  • 3. Overview of the Hatch-Waxman Act and its impact on the drug development process.
    Mossinghoff GJ.
    Food Drug Law J; 1999; 54(2):187-94. PubMed ID: 11758572
    [No Abstract] [Full Text] [Related]

  • 4. FDA's role in administering the Hatch-Waxman Act.
    Malkin BJ.
    Food Drug Law J; 1999; 54(2):211-4. PubMed ID: 11758575
    [No Abstract] [Full Text] [Related]

  • 5. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC.
    Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Navigating the Hatch-Waxman Act's safe harbor.
    Jones PB.
    Food Drug Law J; 2002; 57(3):475-89. PubMed ID: 12710407
    [No Abstract] [Full Text] [Related]

  • 8. The biotechnology industry organization's view on Hatch-Waxman reform.
    Schmickel D.
    Food Drug Law J; 1999; 54(2):241-2. PubMed ID: 11758580
    [No Abstract] [Full Text] [Related]

  • 9. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
    Srivastava D.
    Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Issues in the interpretation of 180-day exclusivity.
    Lietzan E, Korn DE.
    Food Drug Law J; 2007; 62(1):49-75. PubMed ID: 17444026
    [No Abstract] [Full Text] [Related]

  • 15. GATT implementation and generic drug approval.
    Safir PO, Lassman SM.
    Food Drug Law J; 1996; 51(2):295-302. PubMed ID: 11820203
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
    Soehnge H.
    Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.